Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04567303 · ClinicalTrials.gov registry record · Phase 1

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

A Phase 1 study of Macular Degeneration, sponsored by Hoffmann-La Roche.

Active
Registry status
Phase 1
Development phase
177
Enrollment target
20
Study locations

NCT04567303 is a Phase 1 study of Macular Degeneration that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 177 participants, roughly in line with the 172-participant average among 26 other Macular Degeneration trials with a reported enrollment target. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04567303, a Phase 1 study of Macular Degeneration, is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
177 participants
Enrollment target
20
Study locations

Study Summary

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).

Conditions Studied

Macular Degeneration

Interventions

  • DRUG Zifibancimig
  • DRUG Ranibizumab
  • DEVICE Port Delivery Platform

Study Locations (20)

California

  • The Retina Partners - Encino
  • Retinal Consultants Med Group - Sacramento
  • Orange County Retina Med Group - Santa Ana
  • Macula Retina Vitreous Research Institute - Torrance

Florida

  • Retina Specialty Institute - Pensacola
  • Retina Vitreous Assoc of FL - St. Petersburg
  • Southern Vitreoretinal Assoc - Tallahassee
  • Retina Associates of Florida, LLC - Tampa

Maryland

  • The Retina Care Center - Baltimore
  • Johns Hopkins Med - Baltimore
  • Retina Group of Washington - Chevy Chase
  • Cumberland Valley Retina Consultants - Hagerstown

Arizona

  • Barnet Dulaney Perkins Eye Center - Mesa
  • Associated Retina Consultants - Phoenix

Michigan

  • Foundation for Vision Research - Grand Rapids
  • Associated Retinal Consultants - Royal Oak

Colorado

  • Southwest Retina Consultants - Durango

Georgia

  • Southeast Retina Center - Augusta

Illinois

  • University Retina and Macula Associates, PC - Oak Forest

Trial Details

FieldValue
Enrollment Target 177 participants
Start Date 2020-10-28
Est. Completion 2026-08-01
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04567303

The ClinicalTrials.gov registry entry for NCT04567303 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 172-participant average among 26 other Macular Degeneration trials with a reported enrollment target. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Zifibancimig is the first listed.

NCT04567303 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT04567303 about?

NCT04567303 is a clinical study titled "Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration". This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).

What is the current status of trial NCT04567303?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2020-10-28. Estimated completion is 2026-08-01.

What conditions does trial NCT04567303 study?

This clinical trial studies the following conditions: Macular Degeneration.

What interventions are being tested in trial NCT04567303?

The interventions under investigation include: Zifibancimig (DRUG), Ranibizumab (DRUG), Port Delivery Platform (DEVICE).

Who is sponsoring clinical trial NCT04567303?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04567303 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Macular Degeneration

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.